Defence, Security, Energy, Utilities, Finance, Pharmaceuticals
Home > Pharmaceuticals > UK

ADC Summit 2013

20th May to 21st May 2013, London, United Kingdom

Overview

Open/Close

SMi are pleased to announce their second annual ADC summit 2013. This event has a world leading speaking faculty that will provide the latest insights on antibody-drug conjugates.

Antibody drug conjugates are at the forefront of targeted chemotherapy for the treatment of cancer. Anticipated use of ADCs over the next 5-10 years in set to increase by 40-50% specifically within cancer research. This huge surge in programme is down to highly succesful clinical trials and results that indicate a leap forward in targeted therapeutic delivery, with monoclonal antibodies being used as a springboard for this huge success.

A unique event held in London, let ADC 2013 show you how and where the latest technologies and clinical data have transformed this field. Hear from recent advances in conjugate chemistry, target selection, novel payload deliveries, future ADC pipelines and regulatory issues.

The event will be presented via case studies by those who are working within the latest patents on new molecules. See the latest clinical data on ADCs pushing through trials in I-IV and methods to select antibody platforms that will be most effective against specific diseases.

Benefits of Attending

Open/Close

Featured Speakers

Open/Close

Who Should Attend

Open/Close
Symantec